NCT03405714View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

November 4, 2020

Study Completion Date

November 4, 2020

Conditions
Epilepsy
Interventions
DRUG

Brivaracetam

"* Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml"

Trial Locations (17)

10467

Ep0065 252, The Bronx

27710

Ep0065 237, Durham

Unknown

Ep0065 502, Hradec Králové

Ep0065 240, Prague

Ep0065 242, Berlin

Ep0065 254, Bielefeld

Ep0065 210, Budapest

Ep0065 224, Budapest

Ep0065 247, Budapest

Ep0065 222, Debrecen

Ep0065 232, Miskolc

Ep0065 264, Milan

Ep0065 238, Pavia

Ep0065 239, Pavia

Ep0065 230, Roma

Ep0065 223, Aguas Calientes

Ep0065 248, Seville

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03405714 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy | Biotech Hunter | Biotech Hunter